id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-279334-j0i9ozsz	McCreary, Erin K	Coronavirus Disease 2019 Treatment: A Review of Early and Emerging Options	2020-03-23		.txt	text/plain	8269	363	44	Most existing preclinical and clinical data on antiviral therapy are derived from other viruses, including SARS-CoV-1 (first reported in 2003), Middle East respiratory syndrome coronavirus ([MERS-CoV] first reported in 2012), and non-coronaviruses (eg, Ebola virus disease). The use of 500 mg of chloroquine by mouth twice daily as the reference for efficacy is rational given initial reports from China [16] , but it is important to note that this dosing still requires validation, and the improved R LTEC values reported are largely driven by the finding that hydroxychloroquine was 7.6 times more potent than chloroquine in vitro. Given this finding, the small numbers in this study, the lack of clinical outcomes presented, the potential for additive toxicity with hydroxychloroquine and azithromycin, and the desperate need to practice good antimicrobial stewardship during the COVID-19 pandemic, we would caution clinicians against using these data to support combination therapy. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)	./cache/cord-279334-j0i9ozsz.txt	./txt/cord-279334-j0i9ozsz.txt